<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00470587</url>
  </required_header>
  <id_info>
    <org_study_id>APACE</org_study_id>
    <nct_id>NCT00470587</nct_id>
  </id_info>
  <brief_title>Advantageous Predictors of Acute Coronary Syndromes Evaluation (APACE) Study</brief_title>
  <acronym>APACE</acronym>
  <official_title>Advantageous Predictors of Acute Coronary Syndromes Evaluation (APACE) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss National Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The triage of patients with suspected acute coronary syndrome in the emergency room is a
      time-consuming diagnostic challenge. Therefore high sensitive early markers for myocardial
      damage are needed for more rapidly rule out of acute myocardial infarction (AMI) - especially
      for the first 3 to 4 hours after onset of chest pain in AMI (&quot;troponin-blind&quot; period).

      Therefore we test the hypothesis that the use meticulous patient history and novel cardiac
      markers can provide a faster detection or exclusion of AMI in patients presenting with acute
      chest pain to the emergency department.

      The prospective cohort study is designed to enrol patients presenting with acute chest pain
      at rest within the last 12 hours to the emergency department. Several blood samples for
      detection of the new markers will be drawn and compared with the gold standard for the
      diagnosis of AMI (high-sensitivity cardiac troponin T). All patients will be contacted by
      telephone at 3, 12, 24 and 60 months to determine functional status, major adverse cardiac
      events (death, myocardial infarction, coronary artery bypass grafting, percutaneous coronary
      intervention), and the results of cardiac examination (stress test, coronary angiography) if
      performed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: The triage of patients with suspected acute coronary syndrome in the emergency
      room is a time-consuming diagnostic challenge. Triage and management of patients with low
      probability of coronary artery disease often cause excessive hospital costs. Therefore high
      sensitive early markers for myocardial damage are needed for more rapidly rule out of acute
      myocardial infarction (AMI).

      Cardiac troponins (T and I) are currently the gold standard for definitive AMI diagnosis due
      to their high sensitivity and specificity for detection of myocardial cell injury.
      Unfortunately, troponin is undetectable by current assays in peripheral blood within 3 to 4
      hours after onset of chest pain in AMI (&quot;troponin-blind&quot; period).

      New cardiac markers such as the novel high-sensitive troponin I/T, ischemia modified albumin
      and placental growth factor have demonstrated certain advantages compared to troponin such as
      high negative predictive value for AMI, earlier verifiability in peripheral blood and
      possible value as independent risk marker. However, clinical evaluation in a large cohort of
      unselected patients presenting to an emergency department is still lacking.

      Aim: To test the hypothesis that the use meticulous patient history and novel cardiac markers
      (including high-sensitive troponin I/T, myeloperoxidase, ischemia modified albumin, placental
      growth factor) can provide a faster detection or exclusion of AMI in patients presenting with
      acute chest pain to the emergency department.

      Patients and Methods: The prospective cohort study is designed to enrol unselected patients
      presenting with acute chest pain at rest within the last 12 hours to the emergency
      department. Several blood samples for detection of the new markers will be drawn (baseline,
      1, 2, 3 and 6 hours) and compared with the gold standard for the diagnosis of AMI
      (high-sensitivity cardiac troponin T). Timing and treatment of patients are left to the
      discretion of the attending physician and will be performed according to the standard house
      routine of the hospital. All patients will be contacted by telephone at 6, 12, 24 and 60
      months to determine functional status, major adverse cardiac events (death, myocardial
      infarction, coronary artery bypass grafting, percutaneous coronary intervention), and the
      results of cardiac examination (stress test, coronary angiography) if performed.

      Expected results: It is our hypothesis that the use meticulous patient history and novel
      cardiac markers can improve the detection of AMI by providing an early diagnosis for AMI with
      a high negative predictive value within the &quot;troponin-blind&quot; period.

      Significance: The earlier detection of myocardial necrosis in peripheral blood could help to
      rule out AMI more rapidly. In addition it will allow a more rapid diagnosis and appropriate
      therapy of AMI. This can lead to a significant improvement in patient management and a
      reduction of in-hospital costs.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic utility of various biomarkers, detailed patient's history and examination as well as ECG findings for the early diagnosis of acute myocardial infarction</measure>
    <time_frame>at admission</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">9000</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Angina, Unstable</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      EDTA plasma, Heparin, Serum, Citrate
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients presenting to the emergency department with typical angina pectoris or other
        thoracic sensations at rest or minor exertion that are suspected to be caused by myocardial
        ischemia. Onset of symptoms within the last 12 hours prior to presentation.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients presenting to the emergency department

          -  Typical angina pectoris or other thoracic sensations that are suspected to be caused
             by myocardial ischemia

          -  Symptoms at rest or minor exertion

          -  Onset of symptoms within the last 12 hours prior to presentation

          -  Written informed consent

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Cardiogenic shock

          -  Terminal kidney disease requiring regular dialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Mueller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Basel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian Mueller, MD</last_name>
    <phone>0041-61-2652525</phone>
    <email>christian.mueller@usb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raphael Twerenbold, MD</last_name>
    <email>raphael.twerenbold@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Masaryk University Brno</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiri Parenica, MD</last_name>
      <email>jiri.parenica@atlas.cz</email>
    </contact>
    <investigator>
      <last_name>Jiri Parenica, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emergency Department San Martino Hospital</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paola Ballarino, MD</last_name>
    </contact>
    <investigator>
      <last_name>Paola Ballarino, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of Silesia</name>
      <address>
        <city>Zabrze</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beata Morawiec, MD</last_name>
      <email>beamorawiec@wp.pl</email>
    </contact>
    <investigator>
      <last_name>Beata Morawiec, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oscar Miro, MD</last_name>
      <phone>0034-93 227 54 00</phone>
      <email>OMIRO@clinic.ub.es</email>
    </contact>
    <investigator>
      <last_name>Oscar Miro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Javier Martín Sánchez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raphael Twerenbold, MD</last_name>
      <phone>0041-61-2652525</phone>
      <email>raphael.twerenbold@usb.ch</email>
    </contact>
    <contact_backup>
      <last_name>Christian Mueller, MD</last_name>
      <phone>0041-61-2652525</phone>
      <email>christian.mueller@usb.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Christian Mueller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raphael Twerenbold, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tobias Reichlin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Rubini Gimenez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudia Stelzig, MsC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jasper Boeddinghaus, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baselland, Standort Bruderholz</name>
      <address>
        <city>Bottmingen</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baselland, Standort Liestal</name>
      <address>
        <city>Liestal</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörg Leuppi, Prof.</last_name>
      <email>joerg.leuppi@ksbl.ch</email>
    </contact>
    <investigator>
      <last_name>Jörg Leuppi, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas Geigy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik St. Anna</name>
      <address>
        <city>Luzern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Olten</name>
      <address>
        <city>Olten</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christiane Arnold, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christiane Arnold, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spital Limmattal</name>
      <address>
        <city>Schlieren</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Zürich</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dagmar Keller, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Dagmar Keller, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Albina Nowak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2007</study_first_submitted>
  <study_first_submitted_qc>May 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2007</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Basel, Switzerland</investigator_affiliation>
    <investigator_full_name>Christian Müller, MD</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>chest pain</keyword>
  <keyword>myocardial infarction</keyword>
  <keyword>unstable angina</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

